European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.
2d
Massive Hepatic Necrosis Drives Acute Liver Failure: Mechanisms, Challenges and Clinical Potential
A new eGastroenterology study reveals that massive hepatic necrosis in acute liver failure results from immune-mediated hepatocyte death and multiple cell death pathways, with liver progenitor ...
EMA committee recommends approval for AbbVie’s Maviret for the treatment of acute hepatitis C infection: North Chicago, Illinois Monday, May 25, 2026, 18:00 Hrs [IST] AbbVie, an ...
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® ...
Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...
National Taiwan University Hospital (NTUH), in collaboration with multiple medical centers across Taiwan, has found that ...
AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of its treatment for acute hepatitis C. The final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results